AUTHOR=Jeon Jin Pyeong , Kim Seonghyeon , Kim Tae Yeon , Han Sung Woo , Lim Seung Hyuk , Youn Dong Hyuk , Kim Bong Jun , Hong Eun Pyo , Park Chan Hum , Kim Jong-Tae , Ahn Jun Hyong , Rhim Jong Kook , Park Jeong Jin , Kim Heung Cheol , Kang Suk Hyung 

TITLE=Association Between Copeptin and Six-Month Neurologic Outcomes in Patients With Moderate Traumatic Brain Injury

JOURNAL=Frontiers in Neurology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.749110

DOI=10.3389/fneur.2021.749110

ISSN=1664-2295

ABSTRACT=<sec><title>Background</title><p>Copeptin has been reported as a predictive biomarker for the prognosis after traumatic brain injury (TBI). However, most of them were in patients with severe TBI and limited value in predicting outcomes in patients with moderate TBI defined as Glasgow Coma Scale (GCS) score from 9 to 12. We aimed to investigate the predictive value of copeptin in assessing the neurologic outcome following moderate TBI.</p></sec><sec><title>Methods</title><p>Patients were prospectively enrolled between May 2017 and November 2020. We consecutively measured plasma copeptin within 24 h after trauma, days 3, 5, and 7 using ELISA. The primary outcome was to correlate plasma copeptin levels with poor neurologic outcome at 6 months after moderate TBI. The secondary outcome was to compare the prognostic accuracy of copeptin and C-reactive protein (CRP) in assessing the outcome of patient.</p></sec><sec><title>Results</title><p>A total of 70 patients were included for the final analysis. The results showed that 29 patients (41.4%) experienced a poor neurologic outcome at 6 months. Multivariable logistic regression analysis revealed that increased copeptin (odds ration [OR] = 1.020, 95% <italic>CI</italic>: 1.005–1.036), GCS score of 9 or 10 (<italic>OR</italic> = 4.507, 95% <italic>CI</italic>: 1.266–16.047), and significant abnormal findings on CT (<italic>OR</italic> = 4.770; 95% <italic>CI</italic>: 1.133–20.076) were independent risk factors for poor outcomes. Consecutive plasma copeptin levels were significantly different according to outcomes (<italic>p</italic> &lt; 0.001). Copeptin on day 7 exhibited better prognostic performance than CRP with an area under receiver operating characteristic curve (AUROC) difference of 0.179 (95% <italic>CI</italic>: 0.032–0.325) in predicting 6-month poor outcomes.</p></sec><sec><title>Conclusion</title><p>Plasma copeptin level can be a useful marker in predicting 6-month outcomes in patients with moderate TBI.</p></sec>